FindTrial
Sign In

Factor analysis of bone erosion progression in rheumatoid arthritis patients receiving csDMARDs - Analysis using data from the placebo groups of the DRIVE and DESIRABLE studies -

Factor analysis of bone erosion progression in rheumatoid arthritis patients receiving csDMARDs - Analysis using data from the placebo groups of the DRIVE and DESIRABLE studies - - Factor analysis of bone erosion progression in rheumatoid arthritis patients receiving csDMARDs

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000035583
Enrollment
306
Registered
2019-01-18
Start date
2018-10-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Sponsors

Daiichi Sankyo Co.,LTD, Medical Science Department
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who were randomized to the placebo group in the DRIVE and DESIRABLE studies

Exclusion criteria

Exclusion criteria: 1) Patients who did not received investigational medication once even after randomization. 2) Patients who did not have an available X-ray score at baseline and at least one time point after administration.

Design outcomes

Primary

MeasureTime frame
Odds ratio, 95% CI, and P value (univariate and multivariate model) of each factor for the presence/ absence of progression of Erosion score (ES) at 12 months (progression is defined as change in ES >0.5).—

Secondary

MeasureTime frame
-Odds ratio, 95% CI, and P value (univariate and multivariate model) of each factor for the presence/ absence of progression of JSN score at 12 months (progression is defined as change in JSN >0.5). -Odds ratio, 95% CI, and P value (univariate and multivariate model) of each factor for the presence/ absence of progression of TSS score at 12 months (progression is defined as change in TSS >0.5).—

Countries

Japan

Contacts

Public ContactMakiko Kobayashi

Daiichi Sankyo Co.,LTD Medical Science Department, Oncology & Pain Group

kobayashi.makiko.vj@daiichisankyo.co.jp03-6225-1046

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026